ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

TLSI vs XGN // PIOTROSKI F-SCORE QUALITY

TriSalus Life Sciences Inc. (NASDAQ) VS. Exagen Inc. (NASDAQ) • 15-METRIC TALLY: TLSI 3 — XGN 4
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TLSI VS. XGN) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC TLSI XGN SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 84.60% 58.30% +26.30 TLSI /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -7.96% -6.77% -1.19 XGN /fcf-yield <GO>
Operating Margin -59.70% -21.10% -38.60 XGN /operating-margins <GO>
Net Profit Margin -60.00% -30.00% -30.00 XGN /net-margins <GO>
Revenue Growth (YoY) 53.40% 19.70% +33.70 TLSI /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 0.20 — TIE /balance-sheet <GO>
Piotroski F-Score Quality ACTIVE 4/9 4/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 44.9 59.9 -15.00 XGN /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $237.7M $210.8M $26.9M TLSI /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR TLSI REV XGN REV TLSI GROSS % XGN GROSS % TLSI FCF XGN FCF
FY 2025 $45.2M $66.6M 84.6% 58.3% -$18.9M -$14.3M
FY 2024 $29.4M $55.6M 86.1% 59.5% -$41.2M -$13.8M
FY 2023 $18.5M $52.5M — — -$50.6M -$14.5M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TLSI // BETA —
XGN // BETA —